 |
Suzhou, China and Mölndal, SwedenMay 6, 2026 /PRNewswire/ — Suzhou Ribolia Biopharmaceutical Co., Ltd. (Hong Kong Stock Exchange Code: 6938) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure, collectively “Ribolia”) jointly announced another significant breakthrough in their collaborative project on innovative therapies for liver diseases with Boehringer Ingelheim, achieving yet another milestone. This marks the third key milestone successfully reached in their partnership on innovative therapies for liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), signaling the deepening of the collaborative R&D process and a solid step forward in the translational application of siRNA technology in metabolic liver diseases.
MASH is a severe, progressive fatty liver disease that can advance to liver fibrosis, cirrhosis, liver failure, and even liver cancer. Currently, over 200 million people worldwide are affected by MASH, and as the disease burden continues to rise, there is an urgent clinical need for innovative therapies that can slow disease progression and maintain liver health. The core goal of the deep collaboration between Ribolia and Boehringer Ingelheim is to bring more potential treatment options to MASH patients and fill the clinical treatment gap.
Dr. Liming Gan, Co-CEO and Global President of R&D at Ribolia, stated: “The achievement of this milestone is a significant reflection of the effectiveness of our collaboration and further demonstrates Ribolia’s technical expertise and maturity in siRNA drug discovery and liver-targeted delivery. We are deeply proud to have achieved this highly innovative stage-based result through seamless cooperation and relentless efforts. Going forward, Boehringer Ingelheim will continue to drive the development of this program, committed to bringing new treatment options to MASH patients.”
siRNA therapy aims to silence disease-causing genes by targeting their messenger RNA (mRNA). Ribolia’s liver-targeted delivery technology acts on targets that are difficult to reach with traditional small molecules or antibodies through selective uptake by liver cells.
The realization of this milestone fully reflects the efficient outcomes of the collaboration between Ribolia and Boehringer Ingelheim, as well as their shared goal of addressing unmet clinical needs in the fields of liver and cardiometabolic diseases. This achievement further solidifies Ribolia’s position as a strategic partner for global pharmaceutical companies and highlights the commercial value of its siRNA technology platform. Ribolia will continue to deepen the collaboration, striving for further successes in 2026 and beyond.
About Boehringer Ingelheim
Boehringer Ingelheim is a leading global biopharmaceutical company, operating in two business areas: Human Pharma and Animal Health. The company is among the top investors in R&D in the industry, committed to researching breakthrough therapies to address significant unmet medical needs, thereby helping to improve or extend lives. Since its founding in 1885, Boehringer Ingelheim has been an independent, family-owned company, always focusing on long-term development and integrating sustainability across the entire value chain. With approximately 54,300 employees worldwide, serving more than 130 markets, the company is dedicated to creating a healthier and more sustainable future. For more details, please visit: www.boehringer-ingelheim.com.
About Ribolia and Ribocure International R&D Center
Suzhou Ribolia Biopharmaceutical Co., Ltd. (Ribolia, Hong Kong Stock Exchange Code: 6938) is an innovative clinical-stage R&D company based on small interfering RNA (RNAi) technology, dedicated to developing small nucleic acid drugs. Leveraging its innovative R&D capabilities and fully integrated technology platform, Ribolia has established a robust product pipeline aimed at contributing to addressing unmet clinical needs in serious diseases. For more information, please visit www.ribolia.com.
Ribocure Pharmaceuticals AB, a subsidiary of Ribolia, is committed to the global R&D of life-saving oligonucleotide therapies, applying deep experience in translational medicine and clinical development to address truly unmet medical needs for patients with major diseases in the liver, cardiovascular system, kidneys, and oncology, as well as rare diseases. For more information, please visit www.ribocure.com.